Elena Shagisultanova, MD, PhD

Research Interests

Publications

• Shagisultanova E, Gaponova AV, Gabbasov R, Nicolas E, Golemis EA. Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases. Gene. 2015 Aug 1;567(1):1-11. PubMed PMID: 25967390
• Shagisultanova E, Dunbrack RL Jr, Golemis EA. Issues in interpreting the in vivo activity of Aurora-A. Expert Opin Ther Targets. 2015 Feb;19(2):187-200. PubMed PMID: 25384454
• Overholser L, Shagisultanova E, Rabinovitch RA, Kounalakis N, Diamond J, Finlayson CA, Fisher CM, Kabos P, Elias AD, Borges VF, Mayordomo J. Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies. Oncology (Williston Park). 2016 Dec 15;30(12). PubMed PMID: 27987198
• Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA. EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. Mol Cancer Ther. 2016 Oct;15(10):2486-2497. PubMed PMID: 27507850
• Shagisultanova E, Korobeynikov V, Nikonova A, Chernoff J, Borges V, Golemis E. Combination of p21-activated kinase 1 (PAK1) inhibitor FRAX1036 and Aurora-A inhibitor alisertib is effective in hormone receptor-positive breast cancer. Cancer Research 76 (14 Supplement), 1242-1242
• Deihimi S, Lev A, Shagisultanova E, Xiu J, Slifker M, Xu Q, Ross E, Dunbrack R, El-Deiry W. Frequent BRCA2 Somatic Mutations in Colorectal Cancer Patients with Microsatellite Instability (MSI). Cancer Research 76 (14 Supplement), 2751-2751
• Lev A, Shagisultanova E, Deihimi S, Dicker DT, Xui J, El-Deiry WS. A rationale for treatment of colorectal cancer with mitomycin C and crizotinib. Cancer Research 76 (14 Supplement), 4825-4825.
• Mita M, Becerra C, Richards D, Mita A, Shagisultanova E, Osborne C, O'Shaughnessy J, Zhang C, Henner R, Kapoun A, Xu L, Dupont J, Brachmann R, Farooki A, Diamond J. Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with Paclitaxel (P) in patients (pts) with 1st- to 3rd-line metastatic HER2-negative breast cancer (BC). J Clin Oncol 34, 2016 (suppl; abstr 2516).
• Shagisultanova E, Mayordomo J, Elias AD. Triple-negative breast cancer in the elderly. Breast J. 2017 Nov;23(6):627-629. PubMed PMID: 29112794
• Lev A, Deihimi S, Shagisultanova E, Xiu J, Lulla AR, Dicker DT, El-Deiry WS. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. Cancer Biol Ther. 2017 Sep 2;18(9):694-704. PubMed PMID: 28886275
• Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, Gatalica Z, Andrake M, Dunbrack RL, El-Deiry WS. BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. Oncotarget. 2017 Jun 20;8(25):39945-39962. PubMed PMID: 28591715
• Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, Elias A, Kabos P. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?. J Natl Compr Canc Netw. 2017 Apr;15(4):494-503. PubMed PMID: 28404760
• Shagisultanova E, Diamond J, Stopeck A, Pusztai L, O'Regan R, Gradishar W, Brown-Glaberman U, Chalasani P, McSpadden T, Borakove M, Shedin T, Kabos P, Borges V. Abstract OT1-03-06: Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer Cancer Res February 15 2018 (78) (4 Supplement) OT1-03-06; DOI: 10.1158/1538-7445.SABCS17-OT1-03-06
• Schedin TB, Borges VF, Shagisultanova E. Targeting Breast Cancer Triple Thread. International Journal of Breast Cancer
• Korobeynikov V, Borakove M, Feng Y, Wuest WM, Koval AB, Nikonova AS, Serebriiiskii I, Chernoff J, Borges VF, Golemis EA, Shagisultanova E. Combined inhibition of aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer. (manuscript in preparation, to be submitted to Cancer Research).
• Weiss J, Afghahi A, Shagisultanova E, Diamond JR. Approaching Use of CDK4/6 Inhibitors in Metastatic HR , HER2- Breast Cancer. Oncology (Williston Park). 2018 Oct 15;32(10):513-5. PubMed PMID: 30334242
• Schedin TB, Borges VF, Shagisultanova E. Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition. Int J Breast Cancer. 2018;2018:7835095. PubMed PMID: 30018827
• Tejas Patil, Elena Shagisultanova, Virginia F. Borges. "Tucatinib". Drugs of the Future - Clarivate Analytics. Accepted for publication, December 2018
• Shagisultanova, E, Diamond, J, Stopeck, A, Pusztai, L, O'Regan, R, Gradishar, W, Brown-Glaberman, U, Chalasani, P, McSpadden, T, Borakove, M, Shedin, T, Kabos, P, Borges, V. Abstract OT1-03-06: Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer. Cancer Res February 15 2018 (78) (4 Supplement) OT1-03-06; DOI: 10.1158/1538-7445.SABCS17-OT1-03-06
• Shagisultanova, E, Borakove, M, Kabos, P, Borges, V. Abstract P4-07-07: Triple targeted combination therapy with tucatinib, palbociclib and fulvestrant is active in hormone receptor and HER2-positive human breast tumor cell lines. Cancer Res February 15 2019 (79) (4 Supplement) P4-07-07; DOI: 10.1158/1538-7445.SABCS18-P4-07-07
• West AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Med. 2019 Sep;8(12):5609-5618. PubMed PMID: 31407530
• Korobeynikov V, Borakove M, Feng Y, Wuest WM, Koval AB, Nikonova AS, Serebriiskii I, Chernoff J, Borges VF, Golemis EA, Shagisultanova E. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer. Breast Cancer Res Treat. 2019 Sep;177(2):369-382. PubMed PMID: 31254157
• Shagisultanova E, Chalasani P, Brown-Glaberman U, Gradishar W, Brenner A, Stopeck A, Gao D, McSpadden T, Kabos P, Borges V, on behalf of Academic Breast Cancer Research Consortium. Tucatinib, palbociclib and letrozole in HR+/HER2+ metastatic breast cancer: report of phase IB safety cohort. Journal of Clinical Oncology 2019; 37 (15_suppl), 1029-1029
• Shagisultanova E, Borakove M, Kabos P, Borges V. Triple targeted combination therapy with tucatinib, palbociclib and fulvestrant is active in hormone receptor and HER2-positive human breast tumor cell lines. Cancer Research 2019; 79 (4 Supplement), P4-07-07-P4-07-07
• Patil T, Shagisultanova E, Borges VF. Tucatinib. HER2 (ErbB2) inhibitor, treatment of breast and colorectal cancer. Drugs Fut 2019, 44(1): 11 (DOI: 10.1358/dof.2019. 44.1.2895655)
• E. Shagisultanova, L.S. Crump, M. Borakove, J.K. Hall, A.R. Rasti, B.A. Harrison, P. Kabos, T.R. Lyons and V.F. Borges "Triple targeting of breast tumors driven by hormonal receptors and HER2"
• E Shagisultanova, W Gradishar, U Brown-Glaberman, P Chalasani, AJ Brenner, A Stopeck, J Mayordomo, J R. Diamond, P Kabos, VF. Borges. "Interim safety and efficacy analysis of phase IB / II clinical trial of tucatinib, palbociclib and letrozole in patients with hormone receptor and HER2-positive metastatic breast cancer". Proceedings of SABCS December 2020.
• Shagisultanova E, Crump LS, Borakove M, Hall JK, Rasti AR, Harrison BA, Kabos P, Lyons TR, Borges VF. Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. Mol Cancer Ther. 2022 Jan;21(1):48-57. PubMed PMID: 34728571
• Kagihara JA, Shagisultanova E, Afghahi A, Diamond JR. Moving Towards Targeted Therapies for Triple-Negative Breast Cancer. Curr Breast Cancer Rep. 2021 Sep;13(3):216-226. PubMed PMID: 34457184
• Stoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, Diamond JR. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. Breast Cancer Res Treat. 2021 Jun;187(3):883-891. PubMed PMID: 33625615
• Rasti A, Guimaraes-Young A, Datko F, Borges VF, Aisner DL, Shagisultanova E. PIK3CA mutations drive therapeutic resistance in HER2-positive breast cancer. JCO Precision Oncology (accepted)
• Shagisultanova E, Gao D, Callihan E, Parris HJ, Risendal B, Hines LM, Slattery ML, Baumgartner K, Schedin P, John EM, Borges VF. Overall survival is the lowest among young women with postpartum breast cancer. European Journal of Cancer (under revision).
• Richer JN, Spoelstra NS, Winchester A, Wulfkuhle J, Sams SB, Vidal G, Kabos P, Diamond J, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, Borges V, Gao D, Petricoin E, Elias AD. Laboratory analyses of metastatic ER+/Her2-breast cancer treated with fulvestrant plus enzalutamide. Cancer Res July 1 2021 (81) (13 Supplement) 2867; DOI: 10.1158/1538-7445.AM2021-2867
• Shagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner AJ, Stopeck A, Mayordomo J, Diamond JR, Kabos P and Borges VF. Interim safety and efficacy analysis of phase IB / II clinical trial of tucatinib, palbociclib and letrozole in patients with hormone receptor and HER2-positive metastatic breast cancer. Cancer Res February 15 2021 (81) (4 Supplement) PS10-03; DOI: 10.1158/1538-7445.SABCS20-PS10-03
• Elias AD, Fournier M, Vidal GM, Sams S, Spoelsta N, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, Wulfkuhle J, Petricoin E, Carter L, Zolman K, Armstead S, Winchester A, McSpadden T, Crawford G, Borges V, Gao D, Richer J. Phase II randomized trial of fulvestrant with or without enzalutamide in ER+/Her2- primary breast cancer (BC). Cancer Res February 15 2021 (81) (4 Supplement) PS12-06; DOI: 10.1158/1538-7445.SABCS20-PS12-06
• Shagisultanova E, Gao D, Callihan E, Parris HJ, Risendal B, Hines LM, Slattery ML, Baumgartner K, Schedin P, John EM, Borges VF. Overall survival is the lowest among young women with postpartum breast cancer. Eur J Cancer. 2022 Jun;168:119-127. PubMed PMID: 35525161
• Rasti AR, Guimaraes-Young A, Datko F, Borges VF, Aisner DL, Shagisultanova E. PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. JCO Precis Oncol. 2022 Mar;6:e2100370. PubMed PMID: 35357905
• Shagisultanova E, Crump LS, Borakove M, Hall JK, Rasti AR, Harrison BA, Kabos P, Lyons TR, Borges VF. Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2. Mol Cancer Ther. 2022 Jan;21(1):48-57. PubMed PMID: 34728571
• Shagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner AJ, Stopeck A, Parris H, Gao D, McSpadden T, Mayordomo J, Diamond JR, Kabos P, Borges VF. Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR /HER2 Breast Cancer. Clin Cancer Res. 2023 Dec 15;29(24):5021-5030. PubMed PMID: 37363965
• Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL, van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin Iii EF, Gao D, Richer JK. Phase II trial of fulvestrant plus enzalutamide in ER /HER2- advanced breast cancer. NPJ Breast Cancer. 2023 May 20;9(1):41. PubMed PMID: 37210417

Professional Memberships

• American Society of Clinical Oncology (ASCO), Member
• American Society of Hematology (ASH), Member

Practice Locations

• University of Colorado Hospital

• University of Colorado Cancer Center

Specialty Information

• Internal Medicine, Board Certification (2012, 2022)
• Hematology and Oncology, Board Certification (2015, 2015)

• Cancers - Breast Cancer
• Cancers